Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,otherLiab,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,epsForward,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,ENZ,57200000.0,48471800,836000,,2006000,,2006000,13143000,16046000,2067000,2067000,,,,,,0,32797000,30730000,16751000,-61000,,2006000,2006000,315000.0,336859000.0,48656000.0,64967000.0,2414000.0,113623000.0,485000.0,-273645000.0,7452000.0,1268000.0,1479000.0,15089000.0,29214000.0,158000.0,1268000.0,33036000.0,71341000.0,29932000.0,11475000.0,4390000.0,11007000.0,6014000.0,,-30023000,1589000,-31770000,-76000,21000,-1328000,97000,-29447000,-5000,2307000,673000,-1767000,600000,534000,-1747000,42127000.0,en-US,US,EQUITY,True,Delayed Quote,3.66,1630508456,0.0,3.66,3.73,3.65,11459,USD,NYQ,177406800,-14400000,False,False,REGULAR,4,0.0,3.65 - 3.73,us_market,0,"Enzo Biochem, Inc.",3.66,3.66,3.7,10,10,finmb_269828,NYSE,"Enzo Biochem, Inc.",USD,594535,184116,1.8600001,1.0333334,1.8 - 4.85,-1.1899998,-0.24536079,1.8,4.85,1623268800,1623268800,1623268800,135.55556,0.027,-0.39,1.34,3.226389,0.43361115,0.1343952,3.183261,0.47673917,0.1497644,-9.384616,2.7313433,15,America/New_York,EDT,0.9,,,4.85,1.8,3.2264,3.1833,594.53k,184.12k,48.47M,,36.16M,7.83%,57.91%,1.64M,6.88,4.20%,3.41%,1.63M,,,,,,0.00%,,,105:100,"Oct 20, 2004","Jul 30, 2020","Apr 29, 2021",1.14%,-0.14%,-0.09%,2.01%,112.44M,2.34,94.00%,23.77M,2.44M,1.28M,0.0270,,45.02M,0.93,30.11M,46.35,2.44,1.34,-4.78M,-10.37M,Value,10022,Healthcare,408,9,9,"Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing ÂSTAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.",New York,212 583 0100,NY,6,1609372800,1622505600,8,United States,http://www.enzo.com,86400,8,527 Madison Avenue,Diagnostics & Research
t-1,ENZ,53944000.0,48471800,806000,,2302000,,2302000,13305000,15821000,1710000,1710000,,-49000.0,,,,0,31466000,29756000,15645000,592000,,2302000,2302000,393000.0,335688000.0,50242000.0,61789000.0,2526000.0,112031000.0,482000.0,-275651000.0,7452000.0,1270000.0,1381000.0,44536000.0,29949000.0,182000.0,1270000.0,32922000.0,69883000.0,,12095000.0,4428000.0,9258000.0,4432000.0,,-30023000,-3404000,-506000,-94000,-94000,994000,97000,-1378000,42000,-820000,635000,-1052000,-27000,-268000,-506000,39934000.0,en-US,US,EQUITY,True,Delayed Quote,3.66,1630508456,0.0,3.66,3.73,3.65,11459,USD,NYQ,177406800,-14400000,False,False,REGULAR,4,0.0,3.65 - 3.73,us_market,0,"Enzo Biochem, Inc.",3.66,3.66,3.7,10,10,finmb_269828,NYSE,"Enzo Biochem, Inc.",USD,594535,184116,1.8600001,1.0333334,1.8 - 4.85,-1.1899998,-0.24536079,1.8,4.85,1623268800,1623268800,1623268800,135.55556,0.027,-0.39,1.34,3.226389,0.43361115,0.1343952,3.183261,0.47673917,0.1497644,-9.384616,2.7313433,15,America/New_York,EDT,0.9,,,4.85,1.8,3.2264,3.1833,594.53k,184.12k,48.47M,,36.16M,7.83%,57.91%,1.64M,6.88,4.20%,3.41%,1.63M,,,,,,0.00%,,,105:100,"Oct 20, 2004","Jul 30, 2020","Apr 29, 2021",1.14%,-0.14%,-0.09%,2.01%,112.44M,2.34,94.00%,23.77M,2.44M,1.28M,0.0270,,45.02M,0.93,30.11M,46.35,2.44,1.34,-4.78M,-10.37M,Value,10022,Healthcare,408,9,9,"Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing ÂSTAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.",New York,212 583 0100,NY,6,1609372800,1622505600,8,United States,http://www.enzo.com,86400,8,527 Madison Avenue,Diagnostics & Research
t-2,ENZ,51106000.0,48471800,746000,,299000,,299000,10654000,11897000,497000,497000,,-51000.0,,,,0,28655000,28158000,16758000,-198000,,299000,299000,460000.0,334640000.0,54485000.0,59018000.0,2526000.0,113503000.0,479000.0,-277953000.0,7452000.0,1852000.0,1467000.0,45914000.0,33608000.0,178000.0,1852000.0,33822000.0,70302000.0,,12051000.0,4447000.0,8185000.0,7842000.0,,-30023000,-658000,-617000,-113000,-113000,1166000,97000,-1951000,-13000,-1208000,660000,-340000,-2865000,530000,-617000,36694000.0,en-US,US,EQUITY,True,Delayed Quote,3.66,1630508456,0.0,3.66,3.73,3.65,11459,USD,NYQ,177406800,-14400000,False,False,REGULAR,4,0.0,3.65 - 3.73,us_market,0,"Enzo Biochem, Inc.",3.66,3.66,3.7,10,10,finmb_269828,NYSE,"Enzo Biochem, Inc.",USD,594535,184116,1.8600001,1.0333334,1.8 - 4.85,-1.1899998,-0.24536079,1.8,4.85,1623268800,1623268800,1623268800,135.55556,0.027,-0.39,1.34,3.226389,0.43361115,0.1343952,3.183261,0.47673917,0.1497644,-9.384616,2.7313433,15,America/New_York,EDT,0.9,,,4.85,1.8,3.2264,3.1833,594.53k,184.12k,48.47M,,36.16M,7.83%,57.91%,1.64M,6.88,4.20%,3.41%,1.63M,,,,,,0.00%,,,105:100,"Oct 20, 2004","Jul 30, 2020","Apr 29, 2021",1.14%,-0.14%,-0.09%,2.01%,112.44M,2.34,94.00%,23.77M,2.44M,1.28M,0.0270,,45.02M,0.93,30.11M,46.35,2.44,1.34,-4.78M,-10.37M,Value,10022,Healthcare,408,9,9,"Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing ÂSTAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.",New York,212 583 0100,NY,6,1609372800,1622505600,8,United States,http://www.enzo.com,86400,8,527 Madison Avenue,Diagnostics & Research
t-3,ENZ,50391000.0,48471800,1166000,,-3325000,,-3325000,11115000,7850000,-4431000,-4431000,,-41000.0,,,,0,19527000,23958000,11677000,1106000,,-3325000,-3325000,538000.0,334473000.0,54157000.0,58381000.0,2526000.0,112538000.0,479000.0,-278252000.0,7452000.0,1681000.0,1385000.0,47865000.0,32801000.0,144000.0,1681000.0,34398000.0,68765000.0,,9141000.0,4485000.0,7784000.0,8503000.0,31000.0,-30023000,3000,-1451000,-90000,-90000,488000,97000,-6542000,60000,-5061000,629000,232000,-2325000,-763000,-1451000,35964000.0,en-US,US,EQUITY,True,Delayed Quote,3.66,1630508456,0.0,3.66,3.73,3.65,11459,USD,NYQ,177406800,-14400000,False,False,REGULAR,4,0.0,3.65 - 3.73,us_market,0,"Enzo Biochem, Inc.",3.66,3.66,3.7,10,10,finmb_269828,NYSE,"Enzo Biochem, Inc.",USD,594535,184116,1.8600001,1.0333334,1.8 - 4.85,-1.1899998,-0.24536079,1.8,4.85,1623268800,1623268800,1623268800,135.55556,0.027,-0.39,1.34,3.226389,0.43361115,0.1343952,3.183261,0.47673917,0.1497644,-9.384616,2.7313433,15,America/New_York,EDT,0.9,,,4.85,1.8,3.2264,3.1833,594.53k,184.12k,48.47M,,36.16M,7.83%,57.91%,1.64M,6.88,4.20%,3.41%,1.63M,,,,,,0.00%,,,105:100,"Oct 20, 2004","Jul 30, 2020","Apr 29, 2021",1.14%,-0.14%,-0.09%,2.01%,112.44M,2.34,94.00%,23.77M,2.44M,1.28M,0.0270,,45.02M,0.93,30.11M,46.35,2.44,1.34,-4.78M,-10.37M,Value,10022,Healthcare,408,9,9,"Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing ÂSTAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.",New York,212 583 0100,NY,6,1609372800,1622505600,8,United States,http://www.enzo.com,86400,8,527 Madison Avenue,Diagnostics & Research
